Ziqin Liu

METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma.

Lixia Xu, Shuibin Lin, Xiaoxing Li, 2023, Cancer letters.

Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts anti-tumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.

Lixia Xu, Ying Zhang, Xiaoxing Li, 2023, Journal of hepatology.

Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19

X. Cong, Zhi Li, Bojun Liu, 2023, Frontiers in oncology.

Th17 cells secrete TWEAK to trigger epithelial-mesenchymal transition and promote colorectal cancer liver metastasis.

Jun Yu, Ce Tang, Xiaoxue Ren, 2024, Cancer Research.

Bibliometric study of immunotherapy for hepatocellular carcinoma

Bai-meng Zhang, Zhiyi Li, Rui Guo, 2023, Frontiers in immunology.